MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant
Summary
To meet the demand for cancer-treating therapies, Siren Biotechnology is developing a universal AAV immuno-gene therapy platform designed to reduce development and manufacturing timelines, while also working for numerous types of cancer.As part of the award, Siren Biotechnology will receive a wide range of support from MilliporeSigma, including Millipore\xae bioprocessing products, technologies and consultative services, and close partnership with the company to screen different media formulations to help optimize AAV yield. Managed by an experienced team of engineers and scientists, MilliporeSigmas M Lab Collaboration Centers allow customers to explore technical solutions, test applications, assess technologies, and optimize processes. Additionally, MilliporeSigmas Emprove\xae Program combines high-quality products, comprehensive documentation, and customer support to facilitate qualification, risk assessment, and process optimization.Since 2014, the Life Science businesss Advance Biotech Grant Program has awarded technologies and consultation to more than 40 biotechnology companies around the world, supporting their efforts to improve patient outcomes for various diseases such as cancer, brain tumors, osteoarthritis, and cardiovascular disorders. The company is set to award additional grants in APAC in July and EMEA in November, further expanding its commitment to supporting emerging biotech companies worldwide.About the Life Science business of Merck KGaA, Darmstadt, GermanyThe Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices the company is everywhere.